The problem
Treatment for multidrug-resistant tuberculosis (MDR-TB) was long and arduous, in addition to being expensive. Many people with MDR-TB do not access treatment.
Download the project evaluation
Our response
The project aimed to increase the number of patients that have access to MDR-TB drugs to prevent the spread of the disease. The intervention also sought to stabilize the market for MDR-TB drugs by encouraging more manufacturers to enter the space, while at the same time lower the cost of these drugs.
The project significantly increased access to second-line TB treatment and more than tripled its original objective set for 17 countries, while also targeting two additional countries with high burdens of MDR-TB.
The number of health products and manufacturers increased dramatically during the seven years of the project, while prices for some MDR-TB drugs were reduced by almost 40 percent and some regimens by about 30 percent.
